Progress in clinical application of humoral biomarkers for central nervous system inflammatory demyelinating diseases

VernacularTitle:中枢神经系统特发炎性脱髓鞘疾病体液生物标志物临床应用进展
Author: Xiaobo SUN ¹ ; Chunping CUI ; Wei QIU
Author Information

1. 中山大学附属第三医院神经内科，广州　510620
Keywords: Multiple sclerosis; Neuromyelitis optica spectrum disorders; Myelin oligodendrocyte glycoprotein antibody-associated disease; Biomarkers
From: Chinese Journal of Preventive Medicine 2024;58(9):1423-1431
CountryChina
Language:Chinese
Abstract: Central nervous system idiopathic inflammatory demyelinating diseases (CNS-IIDD) is an autoimmune disorder characterized by inflammatory demyelination. The disease follows a course of recurrent attacks and remission, with some cases displaying continuous progression, often resulting in disability. The incidence of CNS-IIDD has been increasing, imposing a substantial burden on both patients′ families and society in recent years. A promising strategy for disease management involves the identification of humoral biomarkers to diagnose CNS-IIDD and predict disease attack and progression. Such biomarkers could aid in identifying individuals at high risk of disability, enabling targeted preventive interventions. This study summarizes advancements in the identification of humoral biomarkers and their potential for predicting disease activity and progression to offer novel insights into the management of CNS-IIDD.